Outcome in adult low-grade glioma
- 25 September 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 69 (13) , 1366-1373
- https://doi.org/10.1212/01.wnl.0000277271.47601.a1
Abstract
Low-grade gliomas (LGGs) represent a vexing clinical problem. Some patients present with readily controllable seizures and will enjoy years of freedom from tumor progression without intervention, whereas others progress rapidly with eventual neurologic decompensation and death. Both radiation and chemotherapy are helpful to many patients, but the optimal timing and sequencing of these therapies remain unknown. Recent studies have informed our understanding of clinical, histologic, and molecular prognostic factors and help provide guidance as to which patients require early intervention and when observation is feasible or warranted. We review contemporary knowledge regarding prognostic factors, our current evidence-based understanding of the roles and timing of radiation and chemotherapy, and ongoing clinical trials that will further elucidate management of LGGs.Keywords
This publication has 54 references indexed in Scilit:
- A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with OligodendrogliomaCancer Research, 2006
- Reclassification of oligoastrocytomas by loss of heterozygosity studiesInternational Journal of Cancer, 2006
- Survival analysis of presumptive prognostic markers among oligodendrogliomasCancer, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumorsInternational Journal of Cancer, 2004
- Prognostic impact ofTP53mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytomaCancer, 2004
- Phase II Trial of Temozolomide in Patients With Progressive Low-Grade GliomaJournal of Clinical Oncology, 2003
- Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular SubsetsThe American Journal of Pathology, 2002
- Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factorOncogene, 1999
- PCV Chemotherapy for Recurrent Oligodendrogliomas and OligoastrocytomasNeurosurgery, 1998